The Neurology Drugs Market share in 2026 represents an important segment of the pharmaceutical industry focused on medicines used to manage neurological disorders. These therapies address conditions affecting the brain, spinal cord, peripheral nerves, and other parts of the nervous system. The market includes treatments for Alzheimer's disease, multiple sclerosis, epilepsy, Parkinson's disease, and other neurological conditions.
According to Fortune Business Insights, the global neurology drugs market size was valued at USD 160.51 billion in 2025 and is projected to grow from USD 173.7 billion in 2026 to USD 267.15 billion by 2034, exhibiting a CAGR of 9.10% during the forecast period. North America dominated the neurology drugs market with a 9.47% market share in 2025.
The increasing prevalence of neurological disorders is a major factor driving the neurology drugs market. Alzheimer's disease, Parkinson's disease, multiple sclerosis, epilepsy, and cerebrovascular diseases are creating significant demand for medicines used in disease management. Increasing awareness initiatives and improved diagnosis rates are further contributing to treatment demand.
The growing aging population is another important factor supporting market development. Neurological disorders are increasingly associated with aging populations, creating demand for long-term disease management. Pharmaceutical companies are responding through research and development programs focused on novel therapies.
However, the high cost of treatment can limit market expansion. Research, clinical trials, and regulatory approval processes for neurology drugs are expensive and time-consuming. These expenses can increase the final cost of therapies and create barriers for patients, while also making market entry challenging for smaller pharmaceutical companies.
Technological advancement is emerging as an important trend in the neurology drugs market. Brain-computer interfaces, artificial intelligence, virtual reality, gene therapy, and advanced neuroimaging techniques are influencing neurological diagnosis, treatment, and rehabilitation. The integration of artificial intelligence, wearable technologies, and remote monitoring tools is also supporting early diagnosis and adherence tracking.
Personalized medicine represents another emerging opportunity. Instead of relying entirely on a one-size-fits-all treatment approach, personalized medicine focuses on therapies designed around an individual's specific disease characteristics. Pharmaceutical companies are increasing research and development activities to identify treatment approaches that can improve effectiveness, reduce side effects, and support patient adherence.
The neurology drugs market has a fragmented competitive structure, with leading pharmaceutical companies maintaining strong product portfolios and global geographic presence. Novartis AG, Bayer AG, Pfizer Inc., and Sanofi are among the prominent companies identified by Fortune Business Insights.
Companies are emphasizing research and development, strategic partnerships, acquisitions, and innovative drug development to strengthen their positions. In November 2024, Novartis AG acquired Kate Therapeutics to expand its presence in neurology drugs. In May 2025, Sanofi acquired Vigil Neuroscience, Inc. to expand its neurology pipeline and strengthen its focus on therapies for neurodegenerative diseases.